The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis.
Clinical trial
Doxycycline
Hygiene
Lymphatic filariasis
Lymphoedema
Morbidity management
Podoconiosis
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
27
11
2019
accepted:
16
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
24
11
2020
Statut:
epublish
Résumé
As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected individuals are left with the sequellae, especially chronic progressive lymphoedema. Currently this is managed by careful attention to limb hygiene to prevent infection. Studies over the past 15 years have suggested that the incorporation of doxycycline treatment may arrest or even reverse progression of lymphoedema. Most of this work has been observational or based on small studies, and if this intervention is effective, studies need to be conducted on a larger scale and under diverse geographical and social conditions before it can be incorporated into treatment policy. The double-blind, placebo-controlled study was designed to investigate the impact of six weeks treatment with doxycycline added to standard limb hygiene on early stage filarial lymphoedema in five sites in Africa and the Indian subcontinent. One site in Cameroon is selected for studying lymphoedema in podoconiosis. Each site was individually powered with the potential to undertake a meta-analysis on completion. Evaluation methods followed those used in Ghana in 2012 with additions resulting from advances in technology. The details of the core protocol and how it was varied to take account of differing situations at each of the sites are provided. The study will enrol up to 1800 patients and will complete in mid-2021. This paper provides details of what challenges were faced during its development and discusses the issues and how they were resolved. In particular, the reasons for inclusion of new technology and the problems encountered with the supply of drugs for the studies are described in detail. By making these details available, it is hoped that the study protocol will help others interested in improving treatment for filarial lymphoedema in the design of future studies. Trial registration India: Clintrials.gov. NCT02929121 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929121 Mali: Clintrials.gov. NCT02927496 registered 7 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT0292749 Sri Lanka: Clintrials.gov. NCT02929134 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929134 Ghana: ISRCTN. 14042737 registered 10 July 2017: https://doi.org/10.1186/ISRCTN14042737 Tanzania: ISRCTN. 65756724 registered 21 July 2017: https://doi.org/10.1186/ISRCTN65756724 Cameroon: ISRCTN. 1181662 registered 25 July 2017: https://doi.org/10.1186/ISRCTN11881662.
Sections du résumé
BACKGROUND
BACKGROUND
As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected individuals are left with the sequellae, especially chronic progressive lymphoedema. Currently this is managed by careful attention to limb hygiene to prevent infection. Studies over the past 15 years have suggested that the incorporation of doxycycline treatment may arrest or even reverse progression of lymphoedema. Most of this work has been observational or based on small studies, and if this intervention is effective, studies need to be conducted on a larger scale and under diverse geographical and social conditions before it can be incorporated into treatment policy.
METHODS/DESIGN
METHODS
The double-blind, placebo-controlled study was designed to investigate the impact of six weeks treatment with doxycycline added to standard limb hygiene on early stage filarial lymphoedema in five sites in Africa and the Indian subcontinent. One site in Cameroon is selected for studying lymphoedema in podoconiosis. Each site was individually powered with the potential to undertake a meta-analysis on completion. Evaluation methods followed those used in Ghana in 2012 with additions resulting from advances in technology. The details of the core protocol and how it was varied to take account of differing situations at each of the sites are provided. The study will enrol up to 1800 patients and will complete in mid-2021.
CONCLUSIONS
CONCLUSIONS
This paper provides details of what challenges were faced during its development and discusses the issues and how they were resolved. In particular, the reasons for inclusion of new technology and the problems encountered with the supply of drugs for the studies are described in detail. By making these details available, it is hoped that the study protocol will help others interested in improving treatment for filarial lymphoedema in the design of future studies. Trial registration India: Clintrials.gov. NCT02929121 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929121 Mali: Clintrials.gov. NCT02927496 registered 7 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT0292749 Sri Lanka: Clintrials.gov. NCT02929134 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929134 Ghana: ISRCTN. 14042737 registered 10 July 2017: https://doi.org/10.1186/ISRCTN14042737 Tanzania: ISRCTN. 65756724 registered 21 July 2017: https://doi.org/10.1186/ISRCTN65756724 Cameroon: ISRCTN. 1181662 registered 25 July 2017: https://doi.org/10.1186/ISRCTN11881662.
Identifiants
pubmed: 32228663
doi: 10.1186/s13071-020-04024-2
pii: 10.1186/s13071-020-04024-2
pmc: PMC7106687
doi:
Substances chimiques
Doxycycline
N12000U13O
Banques de données
ClinicalTrials.gov
['NCT02929121', 'NCT02927496', 'NCT02929134']
ISRCTN
['ISRCTN14042737', 'ISRCTN65756724', 'ISRCTN1181662']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
155Subventions
Organisme : NIAID NIH HHS
ID : K08 AI121422
Pays : United States
Organisme : USAID
ID : AID-OAA-G-14-00008
Organisme : Bundesministerium für Bildung und Forschung
ID : 7694
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2012 Sep;55(5):621-30
pubmed: 22610930
PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004171
pubmed: 26496129
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
Am J Trop Med Hyg. 2009 Oct;81(4):702-11
pubmed: 19815891
Antimicrob Agents Chemother. 2003 Nov;47(11):3630-3
pubmed: 14576133
Am J Trop Med Hyg. 2017 Dec;97(6):1836-1842
pubmed: 29141750
Wkly Epidemiol Rec. 2014 Sep 19;89(38):409-18
pubmed: 25243263
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319
pubmed: 25412180
Trans R Soc Trop Med Hyg. 2018 Sep 1;112(9):417-418
pubmed: 30239941
PLoS Pathog. 2006 Sep;2(9):e92
pubmed: 17044733
Trop Med Int Health. 2008 Oct;13(10):1277-83
pubmed: 18721188
Trop Med Infect Dis. 2019 Jul 09;4(3):
pubmed: 31323942